BIRC5 and B-cell chronic lymphocytic leukemia: As we have shown here and in recent work [34], levels of these targets (e.g. BCLxL and survivin) are exacerbated by terminal differentiation of leukemic cells; indeed, a number of the corresponding inhibitors appear to have potential as treatments for CLL [3, 4, 55, 59–61].